Selling, General, and Administrative Costs: Johnson & Johnson vs MiMedx Group, Inc.

SG&A Expenses: A Decade of Financial Strategies

__timestampJohnson & JohnsonMiMedx Group, Inc.
Wednesday, January 1, 20142195400000090480000
Thursday, January 1, 201521203000000133384000
Friday, January 1, 201619945000000179997000
Sunday, January 1, 201721420000000220119000
Monday, January 1, 201822540000000258528000
Tuesday, January 1, 201922178000000198205000
Wednesday, January 1, 202022084000000181022000
Friday, January 1, 202120118000000198359000
Saturday, January 1, 202219046000000208789000
Sunday, January 1, 202320112000000211124000
Monday, January 1, 202421969000000
Loading chart...

Unlocking the unknown

A Tale of Two Companies: SG&A Expenses Over Time

In the world of corporate finance, Selling, General, and Administrative (SG&A) expenses are a critical measure of a company's operational efficiency. This chart compares the SG&A expenses of two prominent companies, Johnson & Johnson and MiMedx Group, Inc., from 2014 to 2023.

Johnson & Johnson, a global healthcare giant, consistently reported SG&A expenses in the range of $19 billion to $22 billion annually. Despite a slight decline of about 9% from 2014 to 2022, the company maintained a robust financial position. In contrast, MiMedx Group, Inc., a smaller player in the biopharmaceutical sector, saw its SG&A expenses grow by approximately 133% over the same period, reflecting its aggressive expansion strategy.

This comparison highlights the contrasting financial strategies of a well-established corporation versus a rapidly growing company, offering valuable insights into their operational priorities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025